Article

Pfizer Appoints New COO

The company has appointed Albert Bourla, PhD, as its new COO.

Pfizer announced on Nov. 13, 2017 that it appointed Albert Bourla, PhD, as its new COO, effective Jan. 1, 2018.

Since early 2016, Dr. Bourla has been the group president of Pfizer’s innovative health business, and has held a range of senior global positions. He holds a PhD degree in the biotechnology of reproduction from the Veterinary School of Aristotle University.

“The naming of a chief operating officer comes at a time when our business is strong as we continue to advance our strategy while also managing a dynamic and challenging external environment, said Ian Read, Pfizer chairman and CEO.

Source: Pfizer

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related Videos
Tariffs & Trade Policy: Results of a Bio/Pharma Peer Survey
How the 15% US-EU Tariff Cap Affects Bio/pharma
Dave Miller, PhD, Chief Scientific Officer, AustinPx
© 2025 MJH Life Sciences

All rights reserved.